OKG-0303

About Okogen

Okogen is a private, clinical-stage biotech company innovating in the ophthalmic therapeutics space, specifically targeting the large and underserved market for acute infectious conjunctivitis. Its lead asset, OKG-0303, is a fixed-dose combination eye drop in Phase 2b development, aiming to be a 'one-stop-shop' treatment for all major infectious causes of pink eye. The company is led by a team with deep ophthalmic development experience and is positioned to address a significant unmet need, as there are currently no approved treatments for adenoviral conjunctivitis, which comprises over 90% of viral ocular infections.

Therapeutic Areas